Thomas Kindt, chief scientific officer of InNexus, said: “We are beginning a study in cynomolgus monkeys of DXL625, an antibody directed against the B-cell marker CD20 and enhanced in potency with our DXL technology.
“The test is designed to evaluate toxicity and pharmokinetics of our product and to measure B-cell depletion and recovery in this primate species. This study, which takes multiple months to complete and is part of our drug development plan will generate data moving us toward human clinical trial testing with DXL625.”
InNexus has recently announced the addition of a new product designated DXLr120 (CD20). This is the third product added to the growing InNexus pipeline and was developed using new recombinant methods to produce a DXL anti-CD20 antibody.